RFG
BMRN icon

RFP Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

RFP Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-43
Closed -$4.15K – 870
2023
Q4 		$4.15K Hold
43
– – ﹤0.01% 579
2023
Q3 		$3.81K Hold
43
– – ﹤0.01% 551
2023
Q2 		$3.73K Hold
43
– – ﹤0.01% 594
2023
Q1 		$4.18K Hold
43
– – ﹤0.01% 419
2022
Q4 		$4.45K Buy
+43
New +$4.04K ﹤0.01% 544

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RFP Financial Group's BMRN Position: Q1 2024 in Review

RFP Financial Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 43 shares — an estimated $4.15K sold.

RFP Financial Group first reported a position in BMRN in Q4 2022 and held it in 5 quarters. The position peaked at $4.45K in Q4 2022. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • RFP Financial Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • RFP Financial Group sold 43 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $4.15K.
  • RFP Financial Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • RFP Financial Group's BioMarin Pharmaceuticals position peaked at $4.45K in Q4 2022.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on RFP Financial Group's 13F filing for Q1 2024, filed 9 May 2024.